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 Abstract 
3D printing is forecast to be a highly disruptive technology within the 
pharmaceutical sector. In particular, the main benefits of 3D printing lie in the 
production of small batches of medicines each with a tailored dosage, shape, 
size and release characteristics. Manufacture of medicines this way may 
finally lead to the concept of personalised medicines becoming reality. In the 
shorter term, 3D printing could be extended throughout the drug development 
process, ranging from pre-clinical development and clinical trials, through to 
front-line medical care. This review aims to provide a timely perspective on 
the motivations and potential applications of 3D printing pharmaceuticals, as 
well as a practical viewpoint on how 3D printing could be integrated across 
the pharmaceutical space. 
1.0. The Power of 3D Printing Pharmaceuticals 
We are living in a technological era; we stand on the brink of the next 
industrial revolution, where living in a world of cloud-based computing, 
contactless payments and three-dimensional printing (3DP), which were once 
fantasy, have now become reality. The pharmaceutical industry is 
conservative, preferring established manufacturing processes and formulation 
design to ensure product stability, but by understanding and embracing the 
power of innovative technologies to support manufacturing processes the 
industry could revolutionise the way medicines are designed for individual 
patients.  
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By depositing material layer-by-layer, 3DP can fabricate objects of virtually 
any shape and size on demand. Structures are created from a digital 3D file 
obtained using computer-aided design (CAD) software enabling bespoke 
and individualised objects to be readily manufactured. As such, 3DP has 
found applications in many industries, ranging from rapid prototyping in 
engineering to personalised devices in medicine [1, 2].  
 
More recently, the technology has been applied to pharmaceuticals to 
manufacture medical devices [3-5] and ‘printlets’, which is a word that we 
have coined to refer to 3D printed solid oral dosage forms. Thus far, a wide 
range of formulations has been produced, including those containing multiple 
active pharmaceutical ingredients (APIs) [6-8], with different geometries [9] 
and release characteristics [10, 11]. Favourably, the technology enables 
precise dosages to be deposited based on the initial ‘ink’ concentration and 
the physical dimensions of the formulation. Furthermore, in 2016, the first 3D 
printed tablet approved by the Food and Drug Administration (FDA) was 
commercialised for the treatment of epilepsy (Spritam® by Aprecia 
Pharmaceuticals, https://http://www.spritam.com/ - /hcp/zipdose-
technology/manufactured-using-3d-printing).  
 
The introduction of 3DP to pharmaceuticals has the potential to cause a 
paradigm shift in the way that medicines are designed, used and 
manufactured. Conventional pharmaceutical manufacturing processes were 
first introduced around 200 years ago and, despite the significant 
technological advancements in the 21st century, many of these are still in use 
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today. Whilst these methods are cost-effective for large-scale production, they 
can be inherently time consuming, labour intensive and, because of the large 
batch sizes needed, dose inflexible. Using 3DP could revolutionise the way 
that tablets are manufactured, moving away from a ‘one size fits all approach’ 
toward personalised medicines. Indeed, 3DP could be utilised throughout the 
drug development timeline, ranging from pre-clinical development and first-
in-human (FIH) clinical trials through to front-line medical care.  
 
It is more important than ever for the pharmaceutical industry not to resist 
change, but instead to understand and embrace the power of innovative 
technologies to support manufacturing processes. This review aims to discuss 
the motivations and applications of 3DP in pharmaceuticals, associated 
challenges to implementation and to provide a unique and timely perspective 
on how 3DP could be integrated in clinical practice. 
2.0. Motivations of 3D Printing Pharmaceuticals  
3DP has enormous potential to revolutionise the way medicines are produced 
by providing a simple and rapid means of producing customised small or ‘one-
off’ batches. Whilst seven main categories of 3DP technologies have been 
classified [12], within pharmaceuticals, five main 3DP technologies have been 
researched; binder jet printing, fused deposition modelling (FDM), semi-solid 
extrusion, selective laser sintering (SLS) and stereolithography (SLA). 
Examples of the types of formulations that have been produced using each 
technology are provided in Table 1. The purpose of this review is not to 
provide extensive information relating to each 3DP technology, as this has 
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been covered elsewhere [13-16]. In general, each 3DP technology follow a 
common process for printlet production, herein described as the ‘3 Ds of 3D 
printing’ (Figure 1): 
 
1. Design: Printlets are typically designed using CAD software to create a 
3D representation of the object, often by creating a stereolithographic 
(.stl) file. Desired characteristics can be chosen to suit the pre-clinical or 
clinical requirements of the dosage form. The designed templates are 
then transferred to the selected 3D printer, 
2. Develop: Printlets can then be developed by selecting the 3DP 
technology, excipients and printing parameters, which are typically based 
on the API characteristics and desired outcomes, 
3. Dispense: The 3D printer can then be loaded with the drug-loaded 
feedstock. Formulations are prepared in a layer-by-layer fashion, which 
are then ready for ‘dispensing’. This method of production varies 
depending on the printing platform selected. 
 
Using this novel method of formulation production could benefit a number of 
clinical applications, ranging from streamlining the drug development process 
through to creating personalised medicines on the front-line.  
 
2.1. Early Phase Drug Development 
The pharmaceutical industry has faced increasing pressure in recent years to 
maximise the number of successful drugs reaching commercialisation [17]. It 
is widely understood that the rate of drug failure is high during early phase 
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development [18]. It is therefore crucial for companies to rapidly identify 
suitable drugs at low expense as early as possible in the drug development 
process, ideally within pre-clinical studies or first in human (FIH) clinical trials. 
 
The ideal formulation to support early phase development would display high 
dose flexibility, adequate bioavailability, be easy to administer and support 
fast study progression at low cost [19]. However, traditional manufacturing 
processes often do not support this need for rapid progression, with 
procedures being inherently inflexible, lengthy and labour intensive. 
Furthermore, current formulation strategies come alongside a number of 
associated challenges, ranging from issues around drug solubility and stability 
(e.g. for liquid formulations) through to high resource investment and 
inadequate dose flexibility (e.g. for formulated tablets and capsules) 
(https://s3.amazonaws.com/cpsl-
web/kc/library/reducing_the_time_to_develop_and_manufacture_formulations
_for_first_oral_dose_in_humans.pdf) [20]. Adopting 3DP as an alternative 
formulation-manufacturing tool could potentially overcome such challenges. 
The main benefits and disadvantages of using conventional formulations 
compared to 3DP printed tablets are listed in Table 2. In general, the major 
motivations for using 3DP in pre-clinical and FIH trials can be broken down 
into three main categories:  
 
2.1.1. Dose Flexibility 
Within early phase drug development, dose flexibility is a key requirement; in 
FIH trials, it has been estimated that dosing over a 800-fold range is required 
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[17]. Favourably, 3DP is a highly flexible process, which permits easy 
modification of dosages suited to the study needs. Doses could be 
manipulated rapidly and easily by physically modifying the tablet dimensions 
or infill percentage [21]. Changing the physical dimensions enabled one study 
to create printlets covering a wide dose range (60-300 mg) [22]. This could 
provide an easier, more efficient and more precise means of dose evaluation 
and data collection. However, one must be mindful that altering printlet 
geometry could affect drug release and, as such, this would need to be 
accounted for in the study design [9]. A route to overcoming this could be by 
adjusting the ‘feedstock’ concentration whilst maintaining printlet geometry, or 
by producing rapidly dispersible or chewable printlets that permit immediate 
release.  
 
2.1.2. Reduced Labour and Resource Investment 
Using 3DP as an alternative dispensing tool could alleviate conventional 
manufacturing concerns, which often require time- and resource-intensive 
processes. There are a variety of stand-alone, compact 3D printers that could 
be theoretically integrated into a laboratory or clinical trial setting. For example, 
Makerbot sells an FDM printer with dimensions of 29.5x34.9x38.1 cm at a price 
of $1200 (Replicator Mini+, https://http://www.makerbot.com/replicator-mini/). In 
this case, the cost of purchase, as well as the size of required operation space, 
is substantially lower compared with traditional large-scale tableting processes.  
 
3DP can produce printlets in a short time frame, which is an attractive concept 
for resource- or time-constrained settings, such as within pre-clinical formulation 
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development. On demand printing could enable the production of several 
product iterations for testing, enabling formulators to assess factors such as 
excipient inclusion and compatibility. 3D printed prototypes could help to 
increase understanding earlier on within drug development, decreasing time-to-
market and risks of non-adoption 
(https://http://www.stratasysdirect.com/content/white_papers/str_7463_15_sdm
_wp_transform_mfg.pdf). Within FIH trials, producing tailored printlets 
immediately prior to pre-dosing could reduce the length of storage and 
transportation, as well as prevent the need for stability-improving measures 
(e.g. refrigeration or addition of preservatives). This could negate the need for 
long-term accelerated storage testing which typically takes four weeks for probe 
batches, a condition that delays trial entry [19].  
 
2.1.3. Unique Characteristics 
3DP can be used to create simple and complex printlets with unique 
characteristics. Unlike traditional manufacturing processes, an accurate spatial 
distribution of drug and excipients can be attained, opening up the potential for 
a vast array of formulation designs and geometries to be produced [9]. 
Customised printlets could be based on the pharmacokinetic and 
pharmacodynamic characteristics of the animal model or human [23]. Goyanes. 
et al. 3D printed small capsular devices and used PET/CT imaging to explore 
the intestinal behaviour of four different polymer-based devices in rats [24, 25]. 
This demonstrates how 3DP can be used to tailor dosage forms and understand 
release profiles earlier on in drug development. 
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Within FIH trials, printlets could also be tailored to meet the requirements of the 
study design. For example, if blinding is required (a process that prevents the 
participant from knowing which medicine they are receiving [26]), printlets could 
be designed to mask the presence of the drug. In this case, a two-compartment 
device could be printed, comprised of a drug ‘core’ embedded within a larger 
inert polymer tablet [27, 28]. Moreover, thermal 3DP methods (such as FDM) 
could be exploited as a potential enabling strategy (to increase drug 
bioavailability [29]), by creating a solid dispersion of an API within a polymer 
matrix [30, 31].  
 
2.2. Personalised Medicines 
Since the implementation of the Precision Medicines Initiative in the U.S. in 
2015, there has been increased emphasis on moving medical treatment away 
from a ‘one-size-fits-all’ approach towards personalisation [32]. 
Conventionally, tablets are mass manufactured in a few discrete strengths, 
often based on the dose required for a suitable effect in the majority of the 
population [33]. However, it is evident that one dose might not fit all; 
requirements can vary based on a patient’s genetic profile, disease state and 
other factors (e.g. gender, age and weight) [34, 35]. This understanding 
fashioned the field of personalised medicine, which commonly involves 
tailoring therapies to a patient based on their individual characteristics, needs 
and preferences [36]. 3DP could help to accelerate the field of personalised 
medicine by enabling the small batch production of individualised printlets 
directly at the point of care. This process could benefit a number of different 
applications on the front-line:  
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2.2.1. Paediatric and Geriatric Populations 
In young children and the elderly, dosing requirements can be markedly 
different compared to adults due to differences in physical characteristics and 
pharmacokinetics [37]. This can be particularly problematic for those medicines 
that are formulated as a single discrete strength or formulation type. It has 
become common practice for patients or carers to crush or split tablets to 
achieve the target dose. However such practices pose the risks of dose 
variation [38, 39] and dose-dumping for enteric coated tablets [40, 41]. 
Moreover, in the clinic, tailored formulations could be prepared via specials 
manufacture, however this is often attributed with high cost and delays to 
administration.  
 
Printing pharmaceuticals is well suited to overcoming such challenges. Instead, 
clinicians or pharmacists could design a personalised dosage form containing a 
specific dosage and/or drug for each patient, improving treatment efficacy whilst 
reducing the risk of adverse effects [33]. Furthermore, to improve medication 
adherence and understanding, patients could be empowered to design their 
own printlet from a ‘menu’, choosing their desired formulation type and 
geometric factors [42]. This concept was demonstrated by Goyanes et al. [43], 
whereby patient acceptability of a variety of 3D printed tablet shapes, sizes and 
colours was evaluated. Other patient-friendly formulations, such as fast-
dissolving tablets [44-47] and oro-dispersible films [48] have been produced 
using a range of 3DP technologies.  
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2.2.2. Medicines with Complex Dosage Regimes 
Printing technologies could enable personalisation of medicines with complex 
dosage regimes, such as with narrow therapeutic index (TI) drugs [33, 49]. 
Narrow TI medicines are those that have a small difference between the 
therapeutic and toxic dose, whereby inappropriate dosing could lead to 
ineffective treatment outcomes or adverse effects. Instead of manipulating 
conventional fixed strength formulations, 3DP could create a printlet containing 
an exact dosage of drug, simplifying administration and reducing the risk of 
dose variation and medication errors. This has been achieved using FDM to 
print theophylline, a narrow TI drug used to treat asthma [28]. 3DP could also 
be used to simplify drug administration for medicines that have rapid dose 
changes on initiation or reducing regimes, such as with prednisolone [50] and 
budesonide [10, 28].  
With an aging population, polypharmacy (the concurrent use of more than five 
medicines [51]) is an increasing consideration that can cause medication errors 
and non-adherence [52]. Due to the capability for accurate spatial distribution of 
materials, 3DP can be used to produce polypills by combining multiple actives 
and/or dosages into a single formulation [6, 7]. For example, a five-drug cardiac 
polypill was successfully 3D printed containing aspirin, hydrochlorothiazide, 
atenolol, ramipril and pravastatin [8]. However, it must be considered that by 
combining more than one medicine into the same tablet could result in a large 
tablet size, unfavourable for patients with dysphagia.  
 
Encouragingly, by selecting an appropriate polymer, printlets could also be 
developed to have defined drug release profiles (e.g. by using different rate-
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controlling polymers [53-56]. In 2017, Goyanes. et al. [55] demonstrated that 
delayed release tablets could instead be produced by incorporating the drug 
within an enteric polymer, negating the need for an outer enteric shell. 
 
2.2.3. Rapid Administration and Improved Medicines Access 
3DP could be used across a number of healthcare services, ranging from 
primary and secondary care (e.g. community pharmacies or specialist clinics) 
through to tertiary care (e.g. on hospital wards). On demand dispensing in these 
settings could improve medicines access, reduce medicines wastage and 
accelerate discharge times. One-off doses could even be rapidly produced in 
time- or resource-constrained settings, by integrating 3D printers into disaster 
areas, accident & emergency departments, first response units and military 
operations [57].  
 
3DP could easily be integrated with other technological advancements of our 
generation, such as smart health monitors, applications and cloud-based 
computing. In the 21st century, it is now feasible for patients to monitor their own 
vital signs (such as heart rate and blood pressure) using freely accessible 
applications on their smart phone devices [58]. In the future, the clinician could 
access these real-time data within the existing internet infrastructure, enabling 
easy review and modification of treatments or dosages. As 3D printers can be 
remotely controlled, the physician or pharmacist could design a printlet and 
send a prescription to a location with a 3D printer to be dispensed [13]. It could 
also be possible for experienced patients to own their own 3D printers for 
medicine dispensing, facilitating autonomy in the treatment pathway. 
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3.0. Integration of 3D printing into Clinical Pharmacy Practice 
The numerous benefits that 3DP could provide across the drug development 
timeline and within clinical practice are evident. However, it will come as no 
surprise that its integration will come alongside its own challenges [59]. The 
unique features of the 3DP process, combined with the relative lack of clinical 
history and experience compared to more established oral dosage forms and 
manufacturing tools, pose a number of challenges. Most notably, these relate 
to the matter of regulation and safety, with a number of questions still 
remaining unanswered. How can quality control of 3D printed dosage forms 
be ensured? What process controls and acceptance methods will be 
required? And, how can on-demand 3DP of pharmaceuticals be realised in 
practice?  
 
It is likely that the short-term opportunities lie within early phase drug 
development, whereby 3DP integration is likely to be attainable under current 
regulatory pathways. For example, many clinical trial sites already have 
functionality for immediate preparation on site and have established 
manufacturing licenses and quality release protocols 
(https://mhrainspectorate.blog.gov.uk/2016/05/20/manufacture-of-
investigational-medicinal-products-frequently-asked-questions/). A proposed 
pathway could involve the printer ‘feedstock’ being manufactured in-house or at 
an external manufacturing facility and then supplied to the clinical trial site for 
dispensing. However, it is worth considering that many of the current 3DP 
platforms are not amenable for scale up, which could impact the translation of 
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formulations from early phase development to later phases (i.e. Phase II/III 
trials).  
 
For clinical scenarios, however, the road to integration may be more complex. 
Most notably, it remains undecided whether 3DP will constitute as 
extemporaneous preparation or a manufacturing process. Extemporaneous 
preparation involves clinical staff (such as a dispenser or pharmacist) mixing 
together one or more ingredients in response to an individual prescription [60]. 
For the preparation of personalised medicines, 3DP could also be viewed as an 
extemporaneous process: clinical staff would receive an individual order, insert 
a pre-prepared drug-loaded cartridge or prepare the feedstock on site, and then 
press ‘print’ for dispensing.  
 
However, it is likely that, as 3DP is producing a formulation aesthetically similar 
to conventional tablets and capsules, additional testing may be required to 
ensure safety for human dosing. For example, printlets may require 
conventional tests such as content uniformity, disintegration and other 
characterisation procedures (e.g. tablet friability and hardness). It is likely that 
these requirements will vary between the different 3DP processes. The widely 
accepted criteria of tablets having to demonstrate <1% weight loss in friability 
tests would likely be too stringent for binder jet printing, which commonly 
demonstrate poor mechanical strength [61, 62]. As such, traditional quality 
assessment methods proposed by the FDA and pharmacopoeias may need to 
be revised to support 3D printed formulations.  
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Moreover, undertaking such tests (especially those that are destructive, 
expensive or require highly skilled operators) within a clinical setting would be 
impractical. A proposed way to overcome such challenges could be by 
performing quality control checks on the drug-loaded feedstock (i.e. the initial 
ingredients, such as powder or drug-loaded filaments). Alternatively, novel 
methods of non-invasive tablet characterisation methods may be required to 
permit real time batch release, with the location of use and 3D printer type in 
mind. One method could involve process analytical technologies (PAT), such 
as spectroscopic tools including near infrared or raman spectroscopy, which 
have been used to monitor critical quality attributes such as drug content [63, 
64], hardness and disintegration time [65].  
 
In December 2017, the FDA released guidance titled ‘Technical 
Considerations for Additive Manufactured Medical Devices’, which provides 
an initial regulatory insight on the requirements of 3DP for medical 
applications [66]. For both small and large-scale manufacture of oral dosage 
forms, it is clear that all aspects of the printing process will require thorough 
evaluation to ensure product quality (e.g. hardware, software, raw materials 
and supplier, operator training and quality controls). Notably, there are several 
3DP platforms, each with their own unique requirements, ranging from modes 
of operation, material inclusion and post-processing techniques. For the 
selected 3DP process, it will be important to clearly identify each variable that 
could impact final dosage form performance.  
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For example, if using 3DP on demand within a hospital scenario, dosage 
forms may need to be designed based on clinical assessments. As such, a 
clear identification of clinically relevant design parameters (such as geometry 
and infill percentage) and acceptable parameter ranges (e.g. 
minimum/maximum values) will be required [66]. Importantly, fabricating 
different printlet geometries could change drug release, potentially increasing 
research costs and efforts to understand the impact of these parameters. 
Furthermore, different 3DP technologies have different considerations that 
could be important to dosage form design. For example, FDM and SLS use 
heat and a laser, respectively, as part of the 3DP process, both posing the 
risk of premature API degradation [11]. Moreover, SLA is known to induce 
toxicity due to the use of non-pharmaceutical grade excipients [67]. Further to 
this, current commercial 3D printers have not been designed for good 
manufacturing practice (GMP) use; that is, a manufacturing platform that has 
been validated to ensure that the final drug product is safe for human 
consumption 
(https://http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturin
g/ucm169105.htm). Such requirements dictate that the printer parts in contact 
with the formulation must not leach materials and must be easily cleanable 
[68]. As such, further development will be required to ensure that these 
platforms are fit-for-purpose.  
 
Indeed, it is clear that the 'ideal 3D printer' for personalised medicine has not 
yet been developed. Predominantly, this ideal printer would be affordable, 
produce versatile dosage forms with acceptable safety, quality and stability, 
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have low consumption, and be user-friendly for non-experts of 3DP (Figure 2). 
Critically, to enable this ideal technology to be developed and integrated into 
clinical practice, a multidisciplinary team of 3D printer manufacturers, 
formulation scientists, excipient suppliers and pharmaceutical regulators are 
required to come together. Only via an agreed consensus would these 
changes be able to be made, hurdles to be faced and integration to be 
attainable.  
 
Whilst integration of 3DP into clinical practice may be in its infancy, progress is 
being made every day. Conversations between our research group, the 
pharmaceutical industry and regulators have already begun to further 
understand the requirements of each stakeholder. Furthermore, in the U.S., a 
number of initiatives have been implemented, such as the FDA’s Emerging 
Technology Team (EET), which aim to encourage the application of 
technological innovation to product design and manufacturing and have since 
recognised 3DP as a potential manufacturing platform 
(https://http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsa
ndTobacco/CDER/ucm523228.htm). The Center for Drug Evaluation and 
Research Office of Pharmaceutical Quality has also established a 
manufacturing science program to investigate the use of innovative 
technologies in manufacturing, including 3DP [69].These regulatory initiatives 
will likely aid in progressing 3DP from a theoretical prospect to a realistic and 
revolutionary manufacturing tool to support the pharmaceutical industry. 
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4.0. Concluding Remarks 
The power of 3DP in pharmaceuticals is evident. This technology could 
revolutionise formulation production, to move away from mass manufacture to 
producing highly flexible and personalised dosage forms on-demand. Tailored 
formulations could benefit a number of applications, extending from drug 
development (pre-clinical studies and FIH trials) to front-line medical care 
(personalised medicine). The recent FDA approval of the first 3D printed 
tablet (Spritam®) was a significant milestone in this technology’s history. 3DP 
is expected to continue rapidly evolving over the next decade. Progress is 
already being made, with cutting-edge research being published everyday, 
detailing the new possibilities that 3DP can bring.  
 
Despite its substantial progress, using 3DP to produce drug products still 
remains in its infancy. A number of regulatory requirements need to be 
overcome before the widespread integration of 3DP into practice. However, 
the numerous benefits that this technology can bring cannot be overlooked. It 
is critical, now more than ever, for the pharmaceutical industry to not resist 
change, but to instead understand and embrace the power of 3DP in 
pharmaceuticals. 
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API: Active pharmaceutical ingredient; used to describe the pharmaceutically 
active component of the dosage form 
Binder jet printing: a powder bed 3D printing method that uses a binder 
liquid to agglomerate powder particles to create a solid object 
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CAD software: Computer aided design software; used to digitally design the 
3D printed object 
FDM: Fused Deposition Modeling; a thermal extrusion 3D printing method 
FIH trials: first in human clinical trials; represents the first administration of a 
drug in humans to evaluate initial efficacy, toxicology and pharmacokinetics. 
Printlets: A word that we have coined to describe 3D printed oral dosage 
forms  
Semi-solid extrusion: a 3D printing method that is based on the extrusion of 
semi-solid materials (such as gels or pastes) that solidify to create a solid 
object. 
SLA: Stereolithography; a 3D printing method that uses high energy light to 
photopolymerise a liquid resin to create solid parts 
SLS: Selective laser sintering; a powder bed 3D printing method that uses a 
laser to sinter powder particles together to create a solid object 
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Fabrication of novel drug 
delivery devices 
Methylene blue and 
alizarin yellow (dyes) 
PCL and PEO [70] 
Tablets 
Fabrication of fast 
dissolving drug delivery 
device 
Paracetamol and 
alizarin yellow (dye) 
Colloidal SiO2, mannitol, PVP 




Development of near 
zero-order release 
dosage forms 








Avicel PH301, Eudragit E-100, 
RLPO in ethanol or acetone, or 
PVP and Tween 20 in 
deionised water 
[72] 
   




Fabrication of rapidly 
dispersing dosage form 
Levetiracetam 




























Fabrication of immediate 
and extended release 
tablets 
Theophylline 
Eudragit RL or RS or E or HPC 
SSL, varying concentrations of 





Prednisolone PVA [50] 
Oral films Development of oro- Aripiprazole PVA [48] 
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Fabrication of bi-layered 
tablets for respiratory 
tract infections 
Guafenisin 






Fabrication of a complex 
tablet displaying 
sustained release of 
nifedipine and glipizide 








Fabrication of a complex 
tablet comprised of five 




atenolol and ramipril 





Fabrication of oral drug 
loaded tablets using SLS 
Paracetamol 
Kollicoat IR or Eudragit L, 







Progesterone PCL [76] 
   

















PEGDA, PEG 300, 
diphenyl(2,4,6-
timethylbenzoyl)phosphine 
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 High dose flexibility 
 Can be used for pre-clinical and clinical studies 
 Cheap and easy to manufacture 
 Well established preparative techniques 
 Suitable for patients with dysphagia 
 Accelerate FIH trial entry 
 
 Drug stability may be an issue  
 Microbial stability may be an issue  
 May not be suitable for poorly soluble 
compounds 




 High dose flexibility 
 Possible for on-site reconstitution 
 Well established preparative techniques 
 Could be used for both preclinical and clinical 
studies 
 Suitable for patients with dysphagia  
 Automated equipment available for production 
 Only short term stability data required 
 
 Excipients may be needed for re-
suspendibility 
 May not be suitable for bitter APIs that 
require taste masking 
 May not be suitable for poorly soluble 
compounds 






















 Taste masking possible 
 Blinding can be achieved 
 Well established preparative techniques 
 Automated equipment available for production 
 Accelerate FIH trial entry 
 
 Low dose flexibility 
 Requires adequate flow characteristics  
 May not be suitable for poorly soluble, low 
potency or low density compounds 
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Formulated tablets 
and capsules 
 Can be used for commercial formulation 
development 
 Automated equipment available for production 
 Well established preparative techniques 
 Blinding and taste-masking possible if using 
capsules or by coating tablets 
 Amenable for scale-up 
 
 Low dose flexibility 
 Higher resource input (e.g. lengthier 
process, uses higher amounts of API) 
 Often unsuitable for preclinical studies 
 Excipient compatibility studies may be needed 





 High dose flexibility 
 Suitable for formulation development  
 Cheap and easy to manufacture 
 Suitable for paediatrics and patients with 
dysphagia (e.g. older patients) 
 Accelerate FIH trial entry 
 Possibility for on-site preparation 
 Automated equipment available for production 
 Only short term stability data required 
 Taste masking and blinding possible 
 Thermal methods could serve as an enabling 
strategy 
  
 May be unsuitable for thermally labile drugs 
(FDM) 
 Regulatory requirements require addressing 
 Technical challenges need to be overcome 
 Current 3D printers are not amenable for 
scale up, except in the case of binder jetting 
 
[13] 
Table 2  
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Figure and Table Legends (in order of citation): 
Figure 1. The 3 Ds of 3D Printing: Basic principle of 3D printing oral dosage 
forms 
Table 1: Examples of oral dosage forms produced using different 3D printing 
technologies 
Table 2: The advantages and disadvantages of conventional and 3D printing 
processes to produce medicines within FIH trials  
Figure 2. The ‘ideal 3D printer’ for production of personalised medicines 
